Latest Press Releases
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 27, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P....
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
– Co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital – – Proceeds to accelerate clinical programs across bladder cancer including in...
CG Oncology Presents New Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
– 88% (n=28/32) of Evaluable Patients Achieved Complete Response at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070 in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – CG0070 in Combination with KEYTRUDA was Well...
Upcoming Conferences
Come and meet with us at the EAU
Milan, Italy | March 10-13, 2023
Oral presentation
https://eaucongress.uroweb.org/
Come meet with us at the AUA
Chicago, U.S. | April 28-May 1, 2023
Oral presentation
https://www.auanet.org/AUA2023
CG in the News
ENDPOINTS NEWS
November 15, 2022
Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out
WALL STREET JOURNAL
November 15, 2022
Venture Capitalists Back CG Oncology’s Search for New Bladder Cancer Treatment
ENDPOINTS NEWS
November 10, 2022
CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year